+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Obesity Treatment Market by Treatment Type, Route of Administration, Patient Age Group, Gender, Obesity Type, Distribution Channel, End-User - Global Forecast 2026-2032- Product Image
Obesity Treatment Market by Treatment Type, Route of Administration, Patient Age Group, Gender, Obesity Type, Distribution Channel, End-User - Global Forecast 2026-2032- Product Image
Sale

Obesity Treatment Market by Treatment Type, Route of Administration, Patient Age Group, Gender, Obesity Type, Distribution Channel, End-User - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5460255
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Obesity Treatment Market is projected to reach USD 25.46 Billion in 2026. It is expected to continue growing at a CAGR of 15.64%, reaching USD 61.38 Billion by 2032.

Obesity treatment has moved from episodic weight-loss management to evidence-based chronic disease care. The World Health Organization reports that more than 1 billion people were living with obesity in 2022, including 879 million adults and 159 million children and adolescents, making the condition one of the most significant global health burdens.

Demand is being driven by rising cardiometabolic disease, broader clinical acceptance of anti-obesity medications, expanding bariatric and endoscopic options, and payer interest in reducing obesity-linked costs from type 2 diabetes, cardiovascular disease, sleep apnea, osteoarthritis, and certain cancers. Clinical guidelines increasingly position obesity management as long-term care that combines lifestyle intervention, pharmacotherapy, surgical evaluation, behavioral support, and continuous monitoring.

Transformative Shifts in Obesity Care

The obesity treatment landscape is undergoing a structural shift as GLP-1 receptor agonists and dual incretin therapies redefine clinical expectations for durable weight reduction. Landmark trial results, including cardiovascular risk reduction evidence for semaglutide in selected patients with obesity and established cardiovascular disease, have elevated obesity treatment from cosmetic weight loss to risk-based medical intervention.

At the same time, care delivery is becoming multidisciplinary. Nutrition therapy, behavioral health, remote monitoring, pharmacotherapy, bariatric surgery, and maintenance programs are increasingly integrated to improve adherence, minimize weight regain, and support long-term metabolic outcomes. Regulatory agencies and clinical societies are also emphasizing safety surveillance, patient selection, and continuity of care as demand for evidence-backed obesity treatment accelerates.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating obesity treatment by improving patient identification, risk stratification, treatment matching, and adherence support. AI-enabled analytics can mine electronic health records to identify patients with obesity-related complications who may benefit from pharmacotherapy, intensive lifestyle intervention, or bariatric evaluation.

The cumulative impact is strongest where AI supports clinical workflow rather than replacing clinician judgment. Predictive models, connected scales, digital coaching, and automated prior authorization tools can reduce friction in care pathways, while safeguards for bias, privacy, interoperability, and clinical validation remain essential. AI can also support real-world evidence generation by tracking persistence, adverse events, weight trajectories, and cardiometabolic outcomes across diverse patient populations.

Key Regional Insights

North America remains a high-value obesity treatment region due to elevated disease prevalence, strong specialist networks, and fast uptake of novel anti-obesity medications. CDC data show U.S. adult obesity prevalence at 40.3% for August 2021 to August 2023, sustaining demand for medical, surgical, behavioral, and digital interventions, while Canada continues to advance obesity as a chronic disease within guideline-led care. Europe is shaped by universal health systems, health technology assessment, and cost-effectiveness scrutiny, with Germany, France, Italy, Spain, and the United Kingdom balancing prevention priorities with access to advanced pharmacotherapy and bariatric services.

Asia-Pacific is expanding as urbanization, dietary change, and sedentary lifestyles increase obesity and diabetes risk, especially across China, India, Australia, Japan, and South Korea. Latin America, led by Brazil and Mexico, faces high obesity and diabetes burdens but uneven reimbursement and fragmented access to specialist care. The Middle East, particularly GCC markets, is prioritizing obesity because of high diabetes prevalence and national chronic disease strategies, while Africa is managing a dual burden of undernutrition and rising obesity in urban populations, increasing the need for scalable prevention, primary care screening, and affordable treatment pathways.

Key Group Insights

The G7 has the strongest concentration of advanced obesity treatment infrastructure, including clinical research capacity, reimbursement pathways, regulatory maturity, and specialist obesity care. The European Union supports harmonized drug regulation through the European Medicines Agency, while national health systems determine access and cost controls, making evidence generation, comparative effectiveness, and health-economic value critical for adoption.

BRICS countries combine very large patient pools with uneven access to specialist care, creating opportunities for scalable, lower-cost care models, local manufacturing, and primary care-led obesity management. ASEAN markets are influenced by rapid urbanization, nutrition transition, and growing diabetes prevalence, while GCC countries are investing in chronic disease management, digital health infrastructure, and premium healthcare services. NATO is not a health bloc, but its member countries increasingly view metabolic health as relevant to workforce readiness, healthcare system resilience, and long-term productivity.

Key Country Insights

The United States is the most commercially dynamic obesity treatment market because of high prevalence, strong drug adoption, employer interest, specialist capacity, and active debate on insurance coverage. Canada is advancing chronic disease-oriented obesity care through clinical guidelines and multidisciplinary services, while Mexico and Brazil face substantial obesity and diabetes burdens that support demand for accessible pharmacologic, surgical, nutritional, and lifestyle-based solutions.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are expanding obesity services under budget-sensitive public systems, with reimbursement tied to evidence, clinical prioritization, and health technology assessment. Russia presents a large population base with variable access to advanced therapies and specialist obesity management. China and India have enormous addressable populations and rising metabolic disease risk linked to urbanization and lifestyle change, while Japan, South Korea, and Australia show strong demand for clinically validated, guideline-aligned care models that integrate pharmacotherapy, digital support, and long-term monitoring.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based positioning that connects weight reduction with measurable metabolic, cardiovascular, functional, and quality-of-life outcomes. Commercial strategies should align with obesity as a chronic, relapsing disease requiring maintenance therapy, adherence support, individualized escalation, and long-term patient monitoring.

Organizations should expand partnerships with payers, employers, health systems, primary care networks, and digital health platforms to improve access and persistence. Investment in real-world evidence, safety monitoring, supply reliability, clinician education, culturally tailored care, and affordability will be critical as demand outpaces traditional obesity care capacity. Leaders should also prepare for stricter scrutiny around patient selection, long-term safety, discontinuation outcomes, and equitable access.

Research Methodology

This executive summary is developed through secondary research using publicly available, data-backed sources including WHO, CDC, national health agencies, regulatory bodies, peer-reviewed clinical trials, clinical guidelines, and official health system publications. Insights are triangulated across epidemiology, treatment adoption, regulatory activity, reimbursement trends, clinical outcomes, and regional healthcare infrastructure.

The methodology emphasizes verified facts, market-relevant interpretation, and cross-regional comparison. No unsupported market-sizing claims are used; conclusions are framed around documented disease burden, approved therapies, clinical evidence, real-world care dynamics, and observable healthcare system trends. Regional, group, and country insights are synthesized narratively to maintain clarity, and decision-useful context.

Conclusion

Obesity treatment is entering a new phase defined by chronic disease management, advanced pharmacotherapy, multidisciplinary care, and data-enabled patient engagement. The scale of global obesity, combined with clinical evidence linking treatment to broader health outcomes, is expanding the strategic importance of obesity care across healthcare systems.

Organizations that pair scientific credibility with access strategies, digital support, supply resilience, and long-term outcome measurement will be best positioned to capture growth while improving population health. Sustainable success will depend on demonstrating durable outcomes, supporting equitable access, and integrating obesity treatment into routine cardiometabolic care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Obesity Treatment Market, by Treatment Type
7.1. Pharmacological Treatments
7.1.1. Appetite Suppressants
7.1.2. Lipase Inhibitors
7.1.3. GLP-1 Receptor Agonists
7.1.4. Combination Therapies
7.2. Surgical Treatments
7.2.1. Gastric Bypass
7.2.2. Sleeve Gastrectomy
7.2.3. Adjustable Gastric banding
7.2.4. Biliopancreatic Diversion with Duodenal switch
7.3. Device-Based Treatments
7.3.1. Intragastric Balloons
7.3.2. Endoscopic Sleeve Gastroplasty
7.3.3. Electrical Stimulation Systems
8. Obesity Treatment Market, by Route of Administration
8.1. Oral
8.2. Injectable
8.3. Transdermal
9. Obesity Treatment Market, by Patient Age Group
9.1. Adults
9.2. Elderly
9.3. Pediatric
10. Obesity Treatment Market, by Gender
10.1. Male
10.2. Female
11. Obesity Treatment Market, by Obesity Type
11.1. Class I (BMI 30-35)
11.2. Class II (BMI 35-40)
11.3. Class III (Severe/Morbid obesity, BMI =40)
12. Obesity Treatment Market, by Distribution Channel
12.1. Offline
12.2. Online
13. Obesity Treatment Market, by End-User
13.1. Hospitals & Clinics
13.2. Specialty Clinics
13.3. Weight Loss & Wellness Centers
14. Europe Obesity Treatment Market
15. Asia-Pacific Obesity Treatment Market
16. North America Obesity Treatment Market
17. Latin America Obesity Treatment Market
18. Middle East Obesity Treatment Market
19. Africa Obesity Treatment Market
20. NATO Obesity Treatment Market
21. G7 Obesity Treatment Market
22. European Union Obesity Treatment Market
23. BRICS Obesity Treatment Market
24. ASEAN Obesity Treatment Market
25. GCC Obesity Treatment Market
26. United States Obesity Treatment Market
27. China Obesity Treatment Market
28. Germany Obesity Treatment Market
29. Japan Obesity Treatment Market
30. India Obesity Treatment Market
31. United Kingdom Obesity Treatment Market
32. France Obesity Treatment Market
33. Canada Obesity Treatment Market
34. Italy Obesity Treatment Market
35. Australia Obesity Treatment Market
36. South Korea Obesity Treatment Market
37. Spain Obesity Treatment Market
38. Brazil Obesity Treatment Market
39. Russia Obesity Treatment Market
40. Mexico Obesity Treatment Market
41. Competitive Landscape
41.1. Market Concentration Analysis, 2025
41.1.1. Concentration Ratio (CR)
41.1.2. Herfindahl Hirschman Index (HHI)
41.2. Recent Developments & Impact Analysis, 2025
41.3. Product Portfolio Analysis, 2025
41.4. Benchmarking Analysis, 2025
42. Company Profiles
42.1. Novo Nordisk A/S
42.2. Eli Lilly and Company
42.3. WW International, Inc.
42.4. Amgen Inc.
42.5. Noom, Inc.
42.6. AstraZeneca PLC
42.7. Herbalife Ltd.
42.8. Hims & Hers Health, Inc.
42.9. Rhythm Pharmaceuticals, Inc.
42.10. Zealand Pharma A/S
42.11. Omada Health Inc.
42.12. Boston Scientific Corporation
42.13. IEH Biopharma LLC
42.14. Medifast, Inc.
42.15. Sanofi SA
42.16. Takeda Pharmaceutical Company Limited
42.17. Pfizer, Inc.
42.18. Viking Therapeutics, Inc.
42.19. Currax Pharmaceuticals LLC
42.20. ReShape Lifesciences, Inc.
42.21. AbbVie Inc.
42.22. Atkins Nutritionals, Inc.
42.23. BTL Aesthetics
42.24. C.H. Boehringer Sohn AG & Ko. KG
42.25. F. Hoffmann-La Roche Ltd
42.26. GlaxoSmithKline plc.
42.27. Johnson & Johnson Services, Inc.
42.28. Kellogg Company
42.29. Medtronic PLC
42.30. Merck & Co.
42.31. NutriSystem, Inc.
42.32. Olympus Corporation
List of Figures
FIGURE 1. GLOBAL OBESITY TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL OBESITY TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL OBESITY TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL OBESITY TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL OBESITY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL OBESITY TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GENDER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2025 VS 2032 (%)
FIGURE 23. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 25. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 27. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. EUROPE OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. EUROPE OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. AFRICA OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. AFRICA OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. NATO OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. NATO OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. G7 OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. G7 OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. BRICS OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. BRICS OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. ASEAN OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. ASEAN OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. GCC OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. GCC OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. UNITED STATES OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. CHINA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. GERMANY OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. JAPAN OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. INDIA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. FRANCE OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. CANADA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. ITALY OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. AUSTRALIA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. SPAIN OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. BRAZIL OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. RUSSIA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. MEXICO OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL OBESITY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL OBESITY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL OBESITY TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PHARMACOLOGICAL TREATMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PHARMACOLOGICAL TREATMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PHARMACOLOGICAL TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL APPETITE SUPPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL LIPASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GASTRIC BYPASS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GASTRIC BYPASS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GASTRIC BYPASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL SLEEVE GASTRECTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL SLEEVE GASTRECTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL SLEEVE GASTRECTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ADJUSTABLE GASTRIC BANDING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ADJUSTABLE GASTRIC BANDING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ADJUSTABLE GASTRIC BANDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL BILIOPANCREATIC DIVERSION WITH DUODENAL SWITCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL BILIOPANCREATIC DIVERSION WITH DUODENAL SWITCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL BILIOPANCREATIC DIVERSION WITH DUODENAL SWITCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL DEVICE-BASED TREATMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL DEVICE-BASED TREATMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL DEVICE-BASED TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL INTRAGASTRIC BALLOONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL INTRAGASTRIC BALLOONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL INTRAGASTRIC BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ENDOSCOPIC SLEEVE GASTROPLASTY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ENDOSCOPIC SLEEVE GASTROPLASTY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ENDOSCOPIC SLEEVE GASTROPLASTY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ELECTRICAL STIMULATION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ELECTRICAL STIMULATION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ELECTRICAL STIMULATION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ELDERLY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ELDERLY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ELDERLY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL MALE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL MALE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL MALE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL FEMALE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL FEMALE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL FEMALE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CLASS I (BMI 30-35) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CLASS I (BMI 30-35) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CLASS I (BMI 30-35) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CLASS II (BMI 35-40) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CLASS II (BMI 35-40) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CLASS II (BMI 35-40) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CLASS III (SEVERE/MORBID OBESITY, BMI =40) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CLASS III (SEVERE/MORBID OBESITY, BMI =40) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CLASS III (SEVERE/MORBID OBESITY, BMI =40) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL WEIGHT LOSS & WELLNESS CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL WEIGHT LOSS & WELLNESS CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL WEIGHT LOSS & WELLNESS CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. EUROPE OBESITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. EUROPE OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 107. EUROPE OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 108. EUROPE OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 109. EUROPE OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 110. EUROPE OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 111. EUROPE OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 112. EUROPE OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 113. EUROPE OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 114. EUROPE OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 115. EUROPE OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 160. AFRICA OBESITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 161. AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 162. AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 163. AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 164. AFRICA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 165. AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 166. AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 167. AFRICA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 168. AFRICA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 169. AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170. AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 171. NATO OBESITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 172. NATO OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 173. NATO OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 174. NATO OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 175. NATO OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 176. NATO OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 177. NATO OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 178. NATO OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 179. NATO OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 180. NATO OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 181. NATO OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 182. G7 OBESITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 183. G7 OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 184. G7 OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 185. G7 OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 186. G7 OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 187. G7 OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. G7 OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 189. G7 OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 190. G7 OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 191. G7 OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. G7 OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 204. BRICS OBESITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 205. BRICS OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 206. BRICS OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 207. BRICS OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 208. BRICS OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 209. BRICS OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 210. BRICS OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 211. BRICS OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 212. BRICS OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 213. BRICS OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 214. BRICS OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 215. ASEAN OBESITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 216. ASEAN OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 217. ASEAN OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 218. ASEAN OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 219. ASEAN OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 220. ASEAN OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 221. ASEAN OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 222. ASEAN OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 223. ASEAN OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 224. ASEAN OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 225. ASEAN OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 226. GCC OBESITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 227. GCC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 228. GCC OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 229. GCC OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 230. GCC OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 231. GCC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 232. GCC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 233. GCC OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 234. GCC OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 235. GCC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 236. GCC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 237. UNITED STATES OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 238. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 239. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 240. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 241. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 242. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 243. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 245. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 246. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 247. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 248. CHINA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 249. CHINA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 250. CHINA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 251. CHINA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 252. CHINA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 253. CHINA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 254. CHINA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 255. CHINA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 256. CHINA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 257. CHINA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 258. CHINA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 259. GERMANY OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 260. GERMANY OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 261. GERMANY OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 262. GERMANY OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 263. GERMANY OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 264. GERMANY OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 265. GERMANY OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 266. GERMANY OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 267. GERMANY OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 268. GERMANY OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 269. GERMANY OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 270. JAPAN OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 271. JAPAN OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 272. JAPAN OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 273. JAPAN OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 274. JAPAN OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 275. JAPAN OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 276. JAPAN OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 277. JAPAN OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 278. JAPAN OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 279. JAPAN OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 280. JAPAN OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 281. INDIA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 282. INDIA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 283. INDIA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 284. INDIA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 285. INDIA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 286. INDIA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 287. INDIA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 288. INDIA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 289. INDIA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 290. INDIA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 291. INDIA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 292. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 293. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 294. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 295. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 296. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 297. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 298. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 299. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 300. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 301. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 302. UNITED KINGDOM OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 303. FRANCE OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 304. FRANCE OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 305. FRANCE OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 306. FRANCE OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 307. FRANCE OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 308. FRANCE OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 309. FRANCE OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 310. FRANCE OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 311. FRANCE OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 312. FRANCE OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 313. FRANCE OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 314. CANADA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 315. CANADA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 316. CANADA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 317. CANADA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 318. CANADA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 319. CANADA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 320. CANADA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 321. CANADA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 322. CANADA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 323. CANADA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 324. CANADA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 325. ITALY OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 326. ITALY OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 327. ITALY OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 328. ITALY OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 329. ITALY OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 330. ITALY OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 331. ITALY OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 332. ITALY OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 333. ITALY OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 334. ITALY OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 335. ITALY OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 336. AUSTRALIA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 337. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 338. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 339. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 340. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 341. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 342. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 343. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 344. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 345. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 346. AUSTRALIA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 347. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 348. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 349. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 350. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 351. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY DEVICE-BASED TREATMENTS, 2018-2032 (USD MILLION)
TABLE 352. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 353. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 354. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
TABLE 355. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY OBESITY TYPE, 2018-2032 (USD MILLION)
TABLE 356. SOUTH KOREA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 357.

Companies Mentioned

The companies featured in this Obesity Treatment market report include:
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • WW International, Inc.
  • Amgen Inc.
  • Noom, Inc.
  • AstraZeneca PLC
  • Herbalife Ltd.
  • Hims & Hers Health, Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Zealand Pharma A/S
  • Omada Health Inc.
  • Boston Scientific Corporation
  • IEH Biopharma LLC
  • Medifast, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • Viking Therapeutics, Inc.
  • Currax Pharmaceuticals LLC
  • ReShape Lifesciences, Inc.
  • AbbVie Inc.
  • Atkins Nutritionals, Inc.
  • BTL Aesthetics
  • C.H. Boehringer Sohn AG & Ko. KG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services, Inc.
  • Kellogg Company
  • Medtronic PLC
  • Merck & Co.
  • NutriSystem, Inc.
  • Olympus Corporation

Table Information

Report AttributeDetails
No. of Pages180
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 25.46 Billion
Forecasted Market Value ( USD ) by 2032 $ 61.38 Billion
Compound Annual Growth Rate15.6%
Regions CoveredGlobal
No. of Companies Mentioned33

Related Topics

Related Reports

Anti-Obesity Therapeutics Market by Drug Class, Mechanism of Action, Route of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032 - Product Image

Anti-Obesity Therapeutics Market by Drug Class, Mechanism of Action, Route of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Obesity Diagnosis & Treatment Market - Global Forecast 2026-2032 - Product Image

Obesity Diagnosis & Treatment Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Digital Health for Obesity - Global Strategic Business Report - Product Image

Digital Health for Obesity - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Global Digital Health For Obesity Market Size, Share & Industry Analysis Report By Component (Services, Software, and Hardware), By End-use (Patients, Providers, Payers, and Other End-use.), By Regional Outlook and Forecast, 2025 - 2032 - Product Image

Global Digital Health For Obesity Market Size, Share & Industry Analysis Report By Component (Services, Software, and Hardware), By End-use (Patients, Providers, Payers, and Other End-use.), By Regional Outlook and Forecast, 2025 - 2032

  • Report
  • 358 Pages
  • Global
From
Obesity Market Report and Forecast 2025-2034 - Product Image

Obesity Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.